Paeds Cases · endocrinology-diabetes-and-growth
Counsel parents given a new diagnosis of congenital hypothyroidism — OSCE
OSCE communication and shared-planning station: breaking the news of a congenital hypothyroidism diagnosis confirmed after an abnormal newborn bloodspot screen, explaining the screening result and the meaning of the venous thyroid function tests, outlining the levothyroxine treatment and the dose-for-growth monitoring in plain language, and offering honest prognostic framing while addressing fear.
On this page & tools
Target exams
Communication framework
Establish what the parents already understand and fear. Ask them to recount what they have been told and what they have read, and acknowledge their fear directly. Do not correct them before you have heard them; the fear of intellectual disability is the one you will spend the most time addressing, and you address it with the evidence that early treatment protects the developing brain. [1]
Explain the thyroid in plain language. The thyroid is a small gland in the neck that makes a hormone the body needs for energy, growth, and brain development. Your baby's gland did not form fully or does not work as it should, so the hormone is low. The screening test we do on every newborn — a drop of blood from the heel — measures a signal called TSH that rises when the thyroid is underworking, and your baby's was raised. We confirmed it with a blood test and the result is congenital hypothyroidism. [3]
Reassure on cause and guilt. This is not caused by anything you did or did not do in pregnancy. In most cases the gland simply did not develop correctly, and it is one of the commonest conditions newborn screening finds. You did not cause it, and you could not have prevented it — but you have done exactly the right thing by having the screening, because that is how we found it in time. [3]
The treatment and the monitoring plan
Explain the treatment simply and concretely. The treatment is a single tablet of levothyroxine — the identical hormone the thyroid should make — given once a day, crushed and given on an empty stomach before a feed. The dose is worked out for your baby's weight, and as your baby grows we adjust the dose so the hormone level always stays in the right range. Most children take this tablet for life, and it is small, safe, and inexpensive. [4]
Address the fear of intellectual disability with evidence. This is the part that matters most. Because we found this early and will start the tablet now, your baby's brain development is protected. With early treatment, children with congenital hypothyroidism grow and develop like other children, attend mainstream school, and live full and typical lives. The screening programme exists precisely so that we never again see the intellectual disability that untreated congenital hypothyroidism used to cause — and your baby is exactly who it is designed to protect. [1]
Lay out the monitoring in a way the parents can hold. We check your baby's thyroid levels at two weeks and at four weeks to make sure the dose is right, then regularly through the first year and less often after that. At around three years of age we will do a careful test to see whether your child still needs the tablet or whether the condition has resolved — some children have a temporary form. The most common reason a level comes back abnormal is simply that the child has grown and the dose needs adjusting, so please never stop the tablet on your own and always come to the checks. [2] [1]
Close with shared planning and safety-netting
Agree a clear, written plan and a safety net. Give the parents the dose, the administration instructions, the next appointment, and the number to call if they have trouble giving the tablet or their baby becomes unwell. Confirm their understanding by asking them to repeat the plan. Offer a link to a reliable support organisation, and book a follow-up within the week to reinforce the counselling once the shock has settled. [1]
References
- [1]van Trotsenburg P, Stoupa A, Léger J, et al. Congenital Hypothyroidism: A 2020-2021 Consensus Guidelines Update-An ENDO-European Reference Network Initiative Endorsed by the European Society for Pediatric Endocrinology and the European Society for Endocrinology Thyroid, 2021.PMID 33272083
- [2]Léger J, Olivieri A, Donaldson M, et al. European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism J Clin Endocrinol Metab, 2014.PMID 24446653
- [3]Rastogi MV, LaFranchi SH. Congenital hypothyroidism Orphanet J Rare Dis, 2010.PMID 20537182
- [4]Hrytsiuk I, Gilbert R, Logan S, et al. Starting dose of levothyroxine for the treatment of congenital hypothyroidism: a systematic review Arch Pediatr Adolesc Med, 2002.PMID 11980555